We’re thrilled to be attending the annual PEGS Boston Summit from May 11th - 15th. This event provides a great opportunity to gain expert insights on the latest developments in protein and antibody engineering. Meet our Biocytogen team at booth #311 and learn how our animal models and innovative technologies are accelerating developments in biotech!
What is the 2026 PEGS Boston Summit
PEGS Boston Summit is a leading event in the future of biologics. It has a comprehensive program that brings together over 2,000 industry experts in protein and antibody engineering, drug development, immunotherapy, radiotherapy, and AI/ML-driven research. This year’s special focus will be on the power of peptides, covering their therapeutic potential and impact on drug discovery.
Event Overview
Date: May 11th - 15th, 2026
Venue: Omni Boston Hotel at the Seaport, 450 Summer St, Boston, MA 02210
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Boston, MA!
